DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:067080)
South Korea · Delayed Price · Currency is KRW 10,960
+360 (3.40%)
At close: Sep 4, 2026
DAE HWA Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 201,910 | 305,315 | 191,632 | 164,306 | 164,657 | 163,255 | |
Market Cap Growth | -17.31% | 59.32% | 16.63% | -0.21% | 0.86% | -39.51% |
Enterprise Value | 301,416 | 402,655 | 288,813 | 265,142 | 243,200 | 219,445 |
Last Close Price | 10960.00 | 17330.63 | 10776.76 | 9108.92 | 8976.54 | 8745.39 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 44.20 | 184.65 | 360.61 | - | 147.59 | 73.63 |
PS Ratio | 1.36 | 2.13 | 1.28 | 1.16 | 1.25 | 1.39 |
PB Ratio | 2.36 | 3.86 | 2.51 | 2.12 | 2.02 | 1.96 |
P/TBV Ratio | 4.00 | 6.98 | 4.49 | 3.67 | 3.27 | 2.96 |
P/FCF Ratio | - | 117.82 | 218.93 | - | - | 232.62 |
P/OCF Ratio | - | 56.25 | 36.50 | - | 20.10 | 15.72 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.03 | 2.82 | 1.93 | 1.88 | 1.84 | 1.87 |
EV/EBITDA Ratio | 25.66 | 42.70 | 22.02 | 33.85 | 23.41 | 27.08 |
EV/EBIT Ratio | 54.50 | 127.33 | 43.03 | 135.12 | 41.60 | 66.82 |
EV/FCF Ratio | - | 155.38 | 329.96 | - | - | 312.68 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.19 | 1.22 | 1.30 | 1.43 | 1.10 | 0.84 |
Debt / EBITDA Ratio | 8.68 | 10.26 | 7.57 | 14.11 | 8.67 | 8.66 |
Debt / FCF Ratio | - | 37.35 | 113.42 | - | - | 99.96 |
Net Debt / Equity Ratio | 1.10 | 1.15 | 1.20 | 1.25 | 1.00 | 0.62 |
Net Debt / EBITDA Ratio | 8.04 | 9.62 | 6.97 | 12.39 | 7.90 | 6.38 |
Net Debt / FCF Ratio | -37.75 | 34.99 | 104.43 | -10.64 | -4.21 | 73.71 |
Asset Turnover | 0.70 | 0.69 | 0.70 | 0.68 | 0.70 | 0.67 |
Inventory Turnover | 3.00 | 2.89 | 3.35 | 3.86 | 4.10 | 3.85 |
Quick Ratio | 0.26 | 0.22 | 0.25 | 0.29 | 0.33 | 0.49 |
Current Ratio | 0.56 | 0.51 | 0.52 | 0.51 | 0.62 | 0.75 |
Return on Equity (ROE) | 6.12% | 3.00% | 1.08% | -0.65% | 1.48% | 2.31% |
Return on Assets (ROA) | 1.64% | 0.95% | 1.97% | 0.59% | 1.94% | 1.17% |
Return on Invested Capital (ROIC) | 1.95% | 0.91% | 2.15% | 1.16% | 1.97% | 1.04% |
Return on Capital Employed (ROCE) | 5.60% | 3.50% | 7.60% | 2.20% | 5.00% | 3.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.20% | 0.54% | 0.28% | -0.70% | 0.68% | 1.36% |
FCF Yield | -1.24% | 0.85% | 0.46% | -5.55% | -11.84% | 0.43% |
Dividend Yield | 1.38% | - | - | 1.65% | 1.67% | - |
Payout Ratio | 59.69% | 158.90% | 494.43% | - | 235.51% | 118.28% |
Buyback Yield / Dilution | -2.40% | 1.04% | -1.13% | - | -0.33% | -0.87% |
Total Shareholder Return | -1.02% | 1.04% | -1.13% | 1.65% | 1.35% | -0.87% |